Skip to main content
Caplight Logo









Oncobit

Oncobit

Private
SchlierenHealthcare & Life Scienceshttps://oncobit.com/en/

Last Round

Early Funding

Nov 27, 2025

Total Funding Raised

$6.5M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Oncobit AG is a medtech company that has developed a scalable, data-driven cancer monitoring platform based on the quantitative and sensitive detection of cancer markers in liquid biopsies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical Devices, Healthcare Analytics

Business Model

B2B

Customer Profile

Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

liquid biopsycancer monitoringctDNA analysisprecision oncologyAI diagnosticsdigital PCRdPCRcirculating tumor DNActDNAcancer monitoring platformclinical decision supporttreatment response monitoringmelanoma monitoringclinical trial supportIVDR certification

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oncobit Comparables

Compare Oncobit with similar companies based on industry and business-model similarity.

Oncobit comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Hedera Dx
87%
ID SOLUTIONS
77%
Sysmex Corporation
74%

Oncobit Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingNov 27, 2025
Early FundingNov 20, 2024
SeedApr 29, 2021

Key People

Founding team and executive leadership

Claudia Scheckel

Chief Executive Officer

Executive Team

Oncobit Investors

Notable investors and investment history

Oncobit investors
InvestorRounds
Avanteca PartnersSeed
ID SOLUTIONSEarly Funding
GF Group HoldingSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 104% MoM, reaching 1.6K.

  • Jul 25, 2026

    Monthly visitors grew 105% MoM.

Recent news

Latest coverage and updates

  • hiresJun 23, 2026

    Oncobit AG hires Bram Goorden as Chairman.

Oncobit Filings

Explore SEC and related filing metadata, where available.

Oncobit filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Oncobit's valuation, stock price, and market status.

Is Oncobit a public or private company?

Oncobit is a private company.

What is the current stock price of Oncobit?

Oncobit is a private company with no public stock price. No recent secondary market data is available.

How much is Oncobit worth (valuation)?

Valuation information for Oncobit is not publicly available.

Can I buy Oncobit stock?

Oncobit shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Oncobit's last funding round?

Oncobit's most recent funding round was Early Funding on November 27, 2025.

Who are the main investors in Oncobit?

Key investors in Oncobit include Avanteca Partners, ID SOLUTIONS, GF Group Holding.

Will Oncobit IPO soon?

No public IPO plans have been announced for Oncobit.

How can I track Oncobit secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Oncobit's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSchlieren
Employee Range14
Year Founded2018
Last FundingNov 27, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?